Form 8-K SOLAZYME INC For: Nov 13

�

�

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

�

�

FORM 8-K

�

�

Current Report

Pursuant to Section�13 or 15(d) of the

Securities Exchange Act of 1934

November�13, 2014

Date of report (Date of earliest event reported)

�

�

SOLAZYME, INC.

(Exact name of registrant as specified in its charter)

�

�

�

Delaware	�	001-35189	�	33-1077078
(State or Other Jurisdiction of Incorporation)	�	(Commission File Number)	�	(I.R.S. Employer Identification Number)

225 Gateway Boulevard

South San Francisco, CA 94080

(Address of Principal Executive Offices)

94080

(Zip Code)

(650) 780-4777

(Registrant�s Telephone Number, Including Area Code)

Not Applicable

(Former name or former address, if changed since last report.)

�

�

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (see General Instruction A.2 below):

�

�	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

�

�	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

�

�	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

�

�	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

�

�

�

---

Item�5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b)

As disclosed on October�9, 2014, Ann Mather, a director of Solazyme, Inc. (the �Company�) and Chair of the Company�s Audit Committee, informed the Company that she intended to transition her responsibilities as Audit Committee Chair and thereafter intended to resign as Audit Committee Chair and a director of the Company prior to the end of 2014. Consistent with this, on November�13, 2014, Ms.�Mather provided notice of her resignation as a director of the Company, effective as of November�30, 2014.

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

�

	�		�	SOLAZYME, INC.
	�		�	(Registrant)
Date: November 19, 2014	�		�	By:	�	��/s/ PAUL T. QUINLAN
	�		�		�	��Paul T. Quinlan
	�		�		�	��General Counsel

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Middlefield Canadian Income PCC: Net Asset Value(s)
• The Pillar 2 requirement for Aktia decreases by 0.25 percentage points to 1.00%
• Audience Intelligence Company Tunnl Announces Reach & Frequency, Linear TV Measurement Solution